Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07013487 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Enrollment closed, study ongoing · Eligibility criteria expanded, about 12 words · Secondary endpoints: details revised at 24 of 38 entries · 1 more Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 24 of 38 entries
    • Site details revised at 41 of 41 sites
  2. Site details revised at 27 of 41 sitesv25
  3. Trial sites expanded: 36 → 41 locationsv24
  4. Trial sites reduced: 41 → 36 locationsv23
  5. Site details revised at 1 of 41 sitesv22
Show 20 earlier versionsHide 20 earlier versions
  1. Site details revised at 3 of 41 sitesv21
  2. Study sites: 40 to 41v20
  3. Study sites: 39 to 40v19
  4. Study sites: 37 to 39v18
  5. Eligibility criteria expanded, about 11 words Site details revised at 1 of 37 sitesv17 Show 1 more changeShow less
    • Site details revised at 1 of 37 sites

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites: 36 to 37v16
  7. Study sites: 29 to 36 Primary and study completion dates: Feb 2, 2032 to Oct 24, 2031v15 Show 1 more changeShow less
    • Primary and study completion dates: Feb 2, 2032 to Oct 24, 2031
  8. Study sites: 28 to 29v14
  9. Study sites: 26 to 28v13
  10. Study sites: 25 to 26v12
  11. Study sites: 22 to 25v11
  12. Study sites: 21 to 22v10
  13. Study sites: 19 to 21v9
  14. Study sites: 18 to 19v8
  15. Study sites: 17 to 18v7
  16. Study sites: 16 to 17v6
  17. Primary endpoints: 6 to 5 Study sites: 7 to 16 · Secondary endpoints revised (38)v5 Show 2 more changesShow less
    • Study sites: 7 to 16
    • Secondary endpoints revised (38)

    See this version in full on ClinicalTrials.gov ↗

  18. Study sites: 4 to 7v4
  19. Study sites: 2 to 4v3
  20. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Start date changed from estimate of Jun 6, 2025 to Jun 11, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Start date changed from estimate of Jun 6, 2025 to Jun 11, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.
Trial Details
NCT Number NCT07013487
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 12,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov